

## Pakistan

### Support for Vaccine: DTP-HepB-Hib This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Pakistan																									
<b>2. Vaccine grant number:</b>	08-PAK-08b-Y, 1115-PAK-04A-X, 16-PAK-04a-X, 1718-PAK-04a-X, 1920-PAK-04a-X, 2023-PAK-04a-X, 0715-PAK-03f-X, 0712-PAK-03f-X, 0810-PAK-4a-X, PAK-NVS-1, PAK-NVS-2, PAK-Lumpsum-1																									
<b>3. Date of Decision Letter:</b>	30/09/2019																									
<b>4. Date of the Partnership Framework Agreement:</b>	19-May-15																									
<b>5. Programme title:</b>	New Vaccine Support (NVS), DTP-HepB-Hib, Routine																									
<b>6. Vaccine type:</b>	DTP-HepB-Hib																									
<b>7. Requested product presentation and formulation of vaccine:</b>	Penta, 1 dose(s) per vial, LIQUID																									
<b>8. Programme Duration:<sup>1</sup></b>	2001-2021																									
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)																									
	2001-2019	2020	2021	Total <sup>2</sup>																						
Programme Budget (US\$)	443,670,453	18,664,000	14,942,000	477,276,453																						
<b>10. Vaccine introduction grant</b>	<table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="width: 20%;">Year</th> <th style="width: 40%;">Grant Number</th> <th style="width: 40%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2002</td> <td style="text-align: center;">PAK-Lumpsum-1</td> <td style="text-align: center;">100,000</td> </tr> <tr> <td style="text-align: center;">2008</td> <td style="text-align: center;">08-PAK-08b-Y</td> <td style="text-align: center;">1,811,000</td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">Disbursement</th> </tr> <tr> <th style="width: 60%;">Disbursement date</th> <th style="width: 40%;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">30 June, 2003</td> <td style="text-align: center;">100,000</td> </tr> <tr> <td style="text-align: center;">18 August, 2010</td> <td style="text-align: center;">811,000</td> </tr> <tr> <td style="text-align: center;">07 February, 2011</td> <td style="text-align: center;">1,000,000</td> </tr> </tbody> </table>				Approval			Year	Grant Number	Amount (US\$)	2002	PAK-Lumpsum-1	100,000	2008	08-PAK-08b-Y	1,811,000	Disbursement		Disbursement date	Amount (US\$)	30 June, 2003	100,000	18 August, 2010	811,000	07 February, 2011	1,000,000
Approval																										
Year	Grant Number	Amount (US\$)																								
2002	PAK-Lumpsum-1	100,000																								
2008	08-PAK-08b-Y	1,811,000																								
Disbursement																										
Disbursement date	Amount (US\$)																									
30 June, 2003	100,000																									
18 August, 2010	811,000																									
07 February, 2011	1,000,000																									
<b>11. Product switch grant</b>	<b>Not applicable</b>																									

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

<b>12. Indicative Annual Amounts:<sup>3</sup></b>		(subject to the terms of the Partnership Framework Agreement, if applicable)		
<b>Type of supplies to be purchased with Gavi funds</b>		<b>2001-2019</b>	<b>2020</b>	
Number of vaccine doses			15,199,600	
Annual Amounts (US\$)		443,670,453	18,664,000	
<b>13. Procurement agency:</b>		UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
<b>14. Self-procurement:</b>		Self-procurement applies to co-financed portion.		
<b>15. Co-financing obligations:</b>		According to the co-financing policy, the Country falls within the group: Preparatory transition phase		
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
Type of supplies to be purchased with Country funds in each year	<b>FY 2020/2021</b>	<b>FY 2021/2022</b>	<b>FY 2022/2023</b>	<b>FY 2023/2024</b>
Number of vaccine doses	6,000,200	5,387,900	6,196,100	7,125,500
Number of AD syringes	6,285,900	5,644,500	6,491,100	7,464,800
Number of re-constitution syringes	-	-	-	-
Number of safety boxes	69,175	62,100	71,425	82,125
Value of vaccine doses (US\$)	6,960,181	6,249,924	7,187,412	8,265,524
Total co-financing payments (US\$) (including freight)	7,652,500	6,871,500	7,902,000	9,087,500
In order to mitigate risks of stocking out in 2020, co-financing obligation associated with this program should be fulfilled by September 2020.				
<b>16. Operational support for campaigns:</b>		<b>Not applicable</b>		
<b>17. Additional Reporting Requirements:</b>				
		Due dates		
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:				
<ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> </ul>		31 March 2020		
		15 May 2020		

<ul style="list-style-type: none"> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>
<p><b>18. Financial clarifications:</b></p> <p>Not applicable</p>	
<p><b>19. Other conditions:</b></p> <p>Not applicable</p>	

Signed by,

**On behalf of Gavi**



Thabani Maphosa  
 Managing Director, Country Programmes  
 30/09/2019